SELECT Cardiovascular Outcome Trial: Old Lessons and New Learning
In this medfyle
Key outcomes from the SELECT trial were presented at Obesity Week 2024, including the impact of semaglutide on prediabetes – and exciting CV results in the absence of weight loss. Discussion around the long-term results highlight what is known about adverse effects and tolerability, and position semaglutide as a medication for obesity which can deliver disease modification and reduce CV events.
About this Medfyle
©2024 Medfyle. All rights reserved.
Source: Ryan D, Kushner R, Lincoff AM, et al. SELECT Cardiovascular Outcome Trial: Old Lessons and New Learning. Presented at ObesityWeek® 2024.
The information and data provided is for information purposes only. The author(s) of the original original presentation had no involvement in the creation of this content.
